Key result
Rivaroxaban achieves complete resolution of pacemaker-induced SVC syndrome at 9 months.
Why the study?
Superior vena cava syndrome due to pacemaker leads is an uncommon complication with limited clinical trials on the use of direct oral anticoagulants for treatment.
Population
An 80-year-old man with pacemaker-induced SVC syndrome
Comparison
Direct oral anticoagulants treatment
Design
Case report
Follow-up
9 months
Authors
Loading...
May warrant rivaroxaban trial in select pacemaker-induced SVC syndrome cases; leaves open confirmation in prospective studies.
Case Report (n=1)
Huang et al. (2023) conducted a case report in Pacemaker-induced superior vena cava syndrome (n=1). Rivaroxaban was evaluated on Symptom resolution. Rivaroxaban (20 mg daily) led to complete resolution of symptoms at 9 months in an 80-year-old man with pacemaker-induced superior vena cava syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: